Lidocaine in bronchoalveolar lavage fluid (BALF) is an inhibitor of eosinophil-active cytokines

Clinical and Experimental Immunology

Volumn 104, Issue 2, 1996, Pages 325-331

  Ohnishi, T ^a,d   Kita, H ^a   Mayeno, A N ^a   Okada, S ^a   Sur, S ^a,c   Broide, D H ^b   Gleich, G J ^a,e  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c EAST CAROLINA UNIVERSITY   (United States)

^d TOCHIGI CANCER CENTER   (Japan)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

Bronchial asthma; Bronchoalveolar lavage fluid; Eosinophil survival activity; IL 5 lidocaine

Indexed keywords

ATROPINE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYTOKINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 5; IPRATROPIUM BROMIDE; LIDOCAINE; METHYLPREDNISOLONE; MIDAZOLAM; THEOPHYLLINE;

ANESTHESIA; ARTICLE; ASTHMA; CELL SURVIVAL; CLINICAL ARTICLE; EOSINOPHIL; HUMAN; INHALATIONAL DRUG ADMINISTRATION; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; LUNG LAVAGE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

EID: 0029892145     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2249.1996.32737.x     Document Type: Article

References (40)

1. Frigas E, Gleich GJ. The cosinophil and the pathophysiology of asthma. J Allergy Clin Immunol 1986; 77:527-37.
2. Wardlaw AJ, Kay AB. The role of the cosinophil in the pathogencsis of asthma (review). Allergy 1987; 42:321-35.
3. Bousquet J, Chanez P, Lacoste JY et al. Eosinophilic inflammation in asthma. N Engl J Med 1990; 323:1033-9.
4. Gleich GJ. The eosinophil and bronchial asthma: current understanding. J Allergy Clin Immunol 1990; 85:422-36.
5. Motojima S, Frigas E, Loegering DA, Gleich GJ. Toxicity of eosinophil cationic proteins for guinea pig tracheal epithelium in vitro. Am Rev Respir Dis 1989; 139:801-5.
6. Hastie AT, Loegering DA, Gleich GJ, Kueppers F. The effect of purified human eosinophil major basic protein on mammalian ciliary activity. Am Rev Respir Dis 1987; 135:848-53.
7. Jacoby DB, Ueki IF, Widdicombe JH, Loegering DA, Gleich GJ, Nadel JA. Effect of human eosinophil major basic protein on ion transport in dog tracheal epithelium. Am Rev Respir Dis 1988; 137:13-16.
8. Frigas E, Loegering DA, Solley GO, Farrow GM, Gleich GJ. Elevated levels of the eosinophil granule major basic protein in the sputum of patients with bronchial asthma. Mayo Clin Proc 1981; 56:345-53.
9. Filley WV, Holley KE, Kephart GM, Gleich GJ. Identification by immunofluorescence of eosinophil granule major basic protein in lung tissues of patients with bronchial asthma. Lancet 1982; 2: 11-16.
10. Wardlaw AJ, Dunnette S, Gleich GJ, Collins JV, Kay AB. Eosinophils and mast cells in bronchoalveolar lavage in subjects with mild asthma: relationship to bronchial hyperreactivity. Am Rev Respir Dis 1988; 137:62-69.
11. Gundel RH, Letts LG, Gleich GJ. Human eosinophil major basic protein induces airway constriction and airway hyperresponsiveness in primates. J Clin Invest 1991; 87:1470-3.
12. Clutterbuck EJ, Sanderson C. Regulation of human eosinophilprecursor production by cytokines: a comparison of recombinant human interleukin-1 (rhIL-1), rhIL-3, rhIL-5, rhIL-6, and rh granulocyte-macrophagc colony-stimulating factor. Blood 1990; 75:1774-9.
13. Saito H, Hatake K, Dvorak AM et al. Selective differentiation and proliferation of hematopoietic cells induced by recombinant human interleukins. Proc Natl Acad Sci USA 1988; 85:2288-92.
14. Rothenberg ME, Owen WF, Silberstein DS, Woods J, Soberman RJ, Austen KF, Stevens RL. Human eosinophils have prolonged survival, enhanced functional properties, and become hypodense when exposed to human interleukin 3. J Clin Invest 1988; 81: 1986-92.
15. Fujisawa T, Abu-Ghazaleh R, Kita H, Sanderson C. Gleich GJ. Regulatory effect of cytokines on eosinophil degranulation. J Immunol 1990; 144:642-6.
16. Yamaguchi Y, Hayashi Y, Sugama Y et al. Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor. J Exp Med 1988; 167:1737-42.
17. Rothenberg ME, Petersen J, Stevens RL, Silberstein DS, McKenzie DT, Austen KF, Owen WF Jr. IL-5-dependent conversion of normodense human eosinophils to the hypodense phenotype uses 3T3 fibroblasts for enhanced viability, accelerated hypodensity and sustained antibody-dependent cytotoxicity. J Immunol 1989; 143:2311-6.
18. Metcalf D, Begley CG, Johnson GR et al. Biologic properties in vitro of a recombinant human granulocyte-macrophage colony-stimulating factor. Blood 1986; 67:37-45.
19. Silberstein DS, Owen WF, Gasson JC et al. Enhancement of human eosinophil cytotoxicity and leukotriene synthesis by biosynthetic (recombinant) granulocyte-macrophage colony-stimulating factor. J Immunol 1986; 137:3290-4.
20. Begley CG, Lopez AF, Nicola NA, Warren DJ, Vadas MA, Sanderson C, Metcalf D. Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors. Blood 1986; 68:162-6.
21. Owen WF, Rothenbcrg ME, Silberstcin DS, Gasson JC, Stevens RL, Austen KF, Soberman RJ. Regulation of human eosinophil viability, density, and function by granulocyte/macrophage colony-stimulating factor in the presence of 3T3 fibroblasts. J Exp Med 1987; 166:129-41.
22. Robinson DS, Hamid Q, Ying S et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326:298-304.
23. Hamid Q, Azzawi M, Ying S et al. Expression of m-RNA for interleukin-5 in mucosal bronchial biopsies from asthma. J Clin Invest 1991; 87:1541-6.
24. Sedgwick JB, Calhoun WJ, Gleich GJ et al. Immediate and late airway response of allergic rhinitis patients to segmental antigen challenge. Characterization of eosinophil and mast cell mediators. Am Rev Respir Dis 1991; 144:1274-81.
25. Ohnishi T, Kita H, Weiler D et al. IL-5 is the predominant eosinophil-active cytokine in the antigen-induced pulmonary late-phase reaction. Am Rev Respir Dis 1993; 147:901-7.
26. Broide DH, Lotz M, Cuomo MJ, Coburn DA, Federman EC, Wasserman SI. Cytokines in symptomatic asthma airways. J Allergy Clin Immunol 1992; 89:958-67.
27. Wallen N, Kita H, Weiler D, Gleich GJ. Glucocorticoids inhibit cytokine-mediated eosinophil survival. J Immunol 1991; 147: 3490-5.
28. American Thoracic Society. Standards for the diagnosis and treatment of patients with chronic obstructive pulmonary disease (COPD) and asthma. Am Rev Respir Dis 1989; 136:225-44.
29. Broide DH, Gleich GJ, Cuomo AJ, Coburn DA, Federman EC, Schwartz LB, Wasserman SI. Evidence of ongoing mast cell and eosinophil degranulation in symptomatic asthma airway. J Allergy Clin Immunol 1991; 88:637-48.
30. Kita H, Ohnishi T, Okubo Y, Weiler D, Abrams JS, Gleich GJ. Granulocyte/macrophage colony-stimulating factor and interleukin 3 release from human peripheral blood eosinophils and neutrophils. J Exp Med 1991; 174:745-8.
31. Rotman B, Papermaster BW. Membrane properties of living mammalian cells as studied by enzymatic hydrosis of fluorogenic esters. Proc Natl Acad Sci USA 1966; 55:134-41.
32. Pullen GR, Chalmers PJ, Nind AP, Nairn RC. Criteria of cell killing in vitro. J Immunol Methods 1981; 43:87-93.
33. Stargel WW, Routledge DA. Lidocaine-therapeutic use and serum concentration monitoring. In: Taylor WJ, Finn AL, eds. Individualizing drug therapy: practical applications of drug monitoring. New York: Gross, Townsend, Frank Inc., 1981; 13:48-67.
34. Chu AJ, Lee JM. Lidocaine inhibits choline uptake and phosphatidylcholine biosynthesis in human leukemia monocyte-like U937 cells. Cell Biochem Function 1994; 12:89-98.
35. Goldstein IM, Lind S, Hoffstein S, Weissmann G. Influence of local anesthetics upon human polymorphonuclear leukocyte function in vitro: reduction of lysosomal enzyme release and superoxide anion production. J Exp Med 1977; 146:483-94.
36. Haines KA, Reibman J, Callegari PE, Abramson SB, Philips MR, Weissmann G. Cocaine and its derivatives blunt neutrophil functions without influencing phosphorylation of a 47-kilodalton component of the reduced nicotinamide-adenine dinucleotide phosphate oxidase. J Immunol 1990; 144:4757-64.
37. Ohsaka A, Saionji K, Sato N, Igari J. Local anesthetic lidocaine inhibits the effect of granulocyte colony-stimulating factor on human neutrophil functions. Exp Hematol 1994; 22:460-6.
38. Kanbara T, Tomoda MK, Sato EF, Ueda W, Manabe M. Lidocaine inhibits priming and protein tyrosine phosphorylation of human peripheral neutrophils. Biochem Pharmacol 1993; 45:1593-8.
39. Sur S, Gleich GJ, Swanson MC, Bartemes KR, Broide DH. Eosinophilic inflammation is associated with elevation of IL-5 in the airways of patients with spontaneous symptomatic asthma. J Allergy Clin Immunol 1995; 96:661-8.
40. Hunt LW, Swedlund HA, Gleich GJ The effect of nebulized lidocaine on severe glucocorticoid-dependent asthma. Mayo Clin Proc, in press.